Health ❯ Healthcare ❯ Cancer Treatment

Targeted Therapy

EGFR Inhibitors Antibody Drug Conjugates Menin Inhibitors EGFR Tyrosine Kinase Inhibitors Drug Approval HER2-directed Therapy NSD2 Inhibition Smart Cancer Drug XPO1 Protein Viral Mimics HER2+ Therapy Daraxonrasib CK1α Inhibition FLT3-ITD Mutation Protein Inhibition Engineered Bacteria CAR T Cell Therapy Tumor Suppressors CD33-Targeted Therapies Research Innovations CAR-T Cell Therapy Antibody-Drug Conjugates MEK Inhibitors Mutation-Specific Treatments DLL3-Targeting Antibodies Glycan-Dependent Therapies Dual Targeting Osimertinib Protein Therapy Aumolertinib EGFR-Tyrosine Kinase Inhibitors HER2 Mutations HER2-positive GEA EGFR-Mutated NSCLC Extracellular Matrix Epigenetic Therapy Chimeric Antigen Receptor Therapy Integrin Beta-6 (IB6) Inhibition PARP Inhibitors EGFR Inhibition Dual Gene Targeting Immune Checkpoint Inhibitors Nectin-4 Therapies Natural Killer Cells Tyrosine Kinase Inhibitors HER2-Directed Therapy Combination Therapy Zongertinib RSPO2 Inhibition MUC16 Protein Patient Care KRAS G12C Inhibitors Trastuzumab Deruxtecan (T-DXd) Bispecific Antibodies Cabozantinib Belantamab Mafodotin HER2-targeting Drugs CD123-Targeting Therapies siRNA Therapy KRAS Mutations Triple-Negative Breast Cancer NY-ESO-1 Antigen NRF2 Inhibitors RAS Inhibition T-DXd (Enhertu) Her2 Positive Breast Cancer BTK Inhibitors Bruton’s Tyrosine Kinase Inhibitors Datopotamab Deruxtecan ALK Gene Mutations HER2-Positive Therapy Driver Mutations Cold Tumors Alectinib vs Crizotinib KRAS G12D Mutation Encorafenib and Cetuximab EGFR and ALK Mutations PIK3CA Mutations RAS Gene Inhibition Small Molecule Therapy Fibroblast Activation Protein Encorafenib and Binimetinib PI3Kα Inhibitors CDK12 Inhibitors

Enhertu Improves Progression‑Free Survival in Phase 3 HER2‑Mutant Lung Cancer Trial

The topline result could lead AstraZeneca and Daiichi Sankyo to seek regulatory approval to use the drug as first‑line therapy.

AstraZeneca Licenses Global Rights to Zegfrovy From Dizal

Engineered CAR T Cells Targeting MUC16 Control Bladder Tumors in Mice

Selpercatinib Dramatically Cuts Recurrence in Early-Stage RET-Positive Lung Cancer

Zoldonrasib Shows Promising Early Efficacy in KRAS G12D Lung Cancer

CD70-Targeted HIT Cells Eradicate Solid Tumors in Mice

Waterloo Scientists Ready Engineered Tumor‑Eating Bacteria for Preclinical Testing

Study Finds Blood Test Predicts Tarlatamab Benefit in Small Cell Lung Cancer

Tucatinib Added to First-Line HER2 Maintenance Prolongs Progression-Free Survival in Phase 3 Trial

Pirtobrutinib Extends First-Line PFS vs BR and Shows Higher Response Rates Than Ibrutinib in CLL/SLL

KOMET-007 Shows 600 mg Ziftomenib Plus Venetoclax/Azacitidine Achieves Deep Remissions in NPM1‑Mutated AML

Shorter, Chemo-Free Strategies Match or Beat Standard Care in Adult Leukemias at ASH

Final FLAURA2 Data Show Osimertinib Plus Chemotherapy Extends Survival in EGFR-Mutant Lung Cancer

Engineered CAR-T Cells Target PD-L1 to Deliver IL-12 at Tumors, Showing Solid-Tumor Gains in Mice

Glycan-Targeting ‘GlyTR’ Therapy Kills Diverse Cancers in Preclinical Tests

FDA Grants Priority Review for Enhertu Plus Pertuzumab in First-Line HER2-Positive Metastatic Breast Cancer

Preclinical PET Tracer Enables Same-Day Imaging of Nectin-4 in Breast and Bladder Cancers

FAP-Targeted Radioligand Yields Near-Complete Response in Three Solitary Fibrous Tumor Patients

Lung Tumors Reprogram Bone Marrow Progenitors as NRF2 Emerges as a Target

WCLC 2025: Combination Approaches Redraw EGFR-Mutant NSCLC Care